SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-22-271102
Filing Date
2022-10-27
Accepted
2022-10-27 17:13:44
Documents
4

Document Format Files

Seq Description Document Type Size
1 424B5 d358129d424b5.htm 424B5 488842
2 GRAPHIC g358129g05m05.jpg GRAPHIC 63399
3 GRAPHIC g358129g19e51.jpg GRAPHIC 39465
4 GRAPHIC g358129g24e85.jpg GRAPHIC 133632
  Complete submission text file 0001193125-22-271102.txt   811896
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-260069 | Film No.: 221338173
SIC: 2836 Biological Products, (No Diagnostic Substances)